Photobiomodulation (PBM) research has identified wavelength as the single most consequential variable in light-based therapy protocols. Published literature indicates that 635nm red light and 850nm near-infrared (NIR) light interact with tissue through different absorption pathways and reach different anatomical depths. For commercial operators running full-body sessions, understanding these differences is not just academic. It directly informs session design, client outcomes, and how to evaluate equipment specifications. This article translates the peer-reviewed evidence on both wavelengths into practical knowledge for spa directors, wellness operators, and fitness facility managers evaluating full-body red light systems.

What Does 635nm Red Light Actually Do in the Body?

The 635nm wavelength sits near the peak of the visible red spectrum and falls within what researchers call the "optical window" of biological tissue. According to a widely cited review by Hamblin and de Freitas published in the IEEE Journal of Selected Topics in Quantum Electronics, cytochrome c oxidase (CCO), the terminal enzyme in the mitochondrial electron transport chain, absorbs light across red and near-infrared wavelengths. It shows particular photosensitivity in the red band around 620 to 680nm. The leading hypothesis is that photon absorption dissociates inhibitory nitric oxide from CCO, restoring electron transport and increasing adenosine triphosphate (ATP) production at the cellular level.

Tissue penetration at 635nm is generally reported in the literature as approximately 1 to 2mm into skin and superficial tissue layers. This makes 635nm highly relevant for applications where the physiological targets are close to the surface, such as dermal fibroblasts, keratinocytes, superficial capillary beds, and epidermal structures. A 2024 comprehensive review published in the International Journal of Molecular Sciences found that PBM in the red band stimulates cellular chromophores involved in local circulation pathways.

For commercial operators, the practical implication is that 635nm red light addresses the outermost physiological targets in a full-body session. Published evidence positions this wavelength as well-suited for superficial muscle tissue and skin applications where shallow penetration is an asset. The depth profile is predictable and well-characterized in peer-reviewed literature, making dosimetry more manageable at this wavelength than at longer ones.

What Does 850nm Near-Infrared Light Do Differently?

The 850nm wavelength falls in the near-infrared band, outside visible human perception, and behaves fundamentally differently in biological tissue than red light. Published research on tissue optics indicates that longer wavelengths scatter less and penetrate significantly deeper. Reported penetration depths for 850nm NIR range from approximately 3 to 5cm in soft tissue under standardized conditions, depending on tissue composition, hydration, and the anatomical site. A review published in Photobiomodulation, Photomedicine, and Laser Surgery examining penetration profiles across multiple wavelengths confirmed that NIR wavelengths consistently outperform visible red light for reaching deeper anatomical structures.

At 850nm, the primary absorption target remains cytochrome c oxidase, but the geometry of that interaction changes because the light reaches tissue layers that 635nm cannot. Hamblin's 2018 review in Photochemistry and Photobiology described how PBM using near-infrared wavelengths acts on mitochondria in deeper musculoskeletal tissue, with implications for joint capsules, tendons, and deeper muscle groups that are inaccessible to red light. The biphasic nature of cellular response is especially important at 850nm. Beneficial effects depend on reaching an adequate but not excessive dose at the target tissue, and overdosing at the surface risks underperforming at depth.

For a commercial full-body system, 850nm NIR expands the physiological reach of a session beyond the skin surface. Published protocols in sports medicine and physical therapy research increasingly use NIR wavelengths when targeting deeper musculoskeletal structures, and the broader clinical literature consistently distinguishes the depth-profile advantages of NIR over visible red light for these applications. Operators evaluating systems for clientele with musculoskeletal or joint-related goals should understand that 850nm coverage is not interchangeable with 635nm coverage.

Why Does Penetration Depth Matter for Commercial Full-Body Sessions?

Penetration depth determines which anatomical targets a session can plausibly reach, and that determines the physiological applications a device can support. A system emitting only 635nm can address superficial targets with precision but cannot reach the joint capsules, synovial tissue, or deeper muscle bellies that lie beyond a few millimeters of tissue depth. Conversely, a system emitting only 850nm may overdose superficial structures while trying to deliver an appropriate dose at depth, creating an uneven irradiance profile across the client's full tissue spectrum.

Published dosimetry literature frames the challenge as matching wavelength to target depth. The concept of the therapeutic window for each wavelength is well-defined in peer-reviewed research: energy delivered above it inhibits cellular response, while energy below it fails to elicit one. For a commercial operator running a two-client-per-hour throughput model, wavelength selection is the primary lever for determining which tissue layers receive a therapeutic-range dose within a fixed session window.

The dual-wavelength approach, combining 635nm and 850nm in a single full-body session, has become standard in commercial PBM protocols because it addresses both the superficial and deeper target layers simultaneously. Published research treats the two wavelengths as complementary rather than interchangeable, each contributing to a different stratum of the overall dose delivered during a session. Operators should treat dual-wavelength coverage as a fundamental baseline specification.

What Is the Biphasic Dose-Response Curve?

The biphasic dose-response curve, also called the Arndt-Schulz curve in PBM literature, describes a fundamental property of photobiomodulation: at low doses, cellular stimulation increases, but at higher doses, the same tissue can become inhibited or return to baseline. This is not unique to light therapy. It is a well-characterized phenomenon in pharmacology and biophysics. In PBM, a 2009 study by Huang, Chen, Carroll, and Hamblin published in Dose-Response first formally characterized the biphasic pattern, and subsequent updates confirmed it across multiple tissue types and irradiance levels.

The practical consequence for commercial operators is that higher irradiance and longer sessions are not automatically better. The evidence suggests that each tissue type has an optimal dose range measured in Joules per square centimeter (J/cm²), and exceeding it produces diminishing or counterproductive results. Session parameters are not interchangeable. Irradiance and duration must be specified together, and adjusting one without the other risks falling outside the effective dose range for the target tissue.

Published research uses the formula:

Dose (J/cm²) = [Irradiance (mW/cm²) x Time (seconds)] / 1000

This means that irradiance specification is inseparable from time specification in any credible commercial PBM protocol. Equipment with higher irradiance can deliver the same Joule-per-square-centimeter dose in a shorter session, which directly improves operator throughput. The biphasic curve also explains why the literature emphasizes precision, as the difference between a stimulatory and an inhibitory dose can be smaller than operators expect.

How Does Irradiance Specification Connect to Commercial Throughput?

Irradiance, measured in milliwatts per square centimeter (mW/cm²), is the rate at which light energy is delivered to the tissue surface. It is distinct from total dose (J/cm²), which also incorporates time. In commercial PBM operations, irradiance is the specification that determines how quickly a therapeutic-range dose can be accumulated during a fixed-length session window. A device with low irradiance requires proportionally longer sessions to accumulate an equivalent dose, whereas a device with higher irradiance achieves the same dose in less time.

The OvationULT operates at 65 mW/cm² irradiance. At this specification, a client can accumulate a meaningful dose within 10 to 20 minutes, which is the session window consistent with published commercial protocols for full-body PBM. For an operator running a standard two-client-per-hour model, this throughput is achievable without compromising dose delivery. If irradiance were substantially lower, either session times would need to extend beyond commercially viable windows, or clients would receive a sub-therapeutic dose per the published dose-response literature.

For operators evaluating competing systems, the irradiance specification should always be read alongside the recommended session length. A device claiming short session times while listing low irradiance presents parameters that do not align with the published dose literature. A device with 65 mW/cm² irradiance and a 10 to 20 minute session window presents a dosimetric profile consistent with the full-body photobiomodulation evidence base.

Why Do Commercial Protocols Use Both 635nm and 850nm Together?

The rationale for combining 635nm and 850nm in commercial full-body systems is comprehensive depth coverage. The two wavelengths together address the full anatomical range from the skin surface to deep musculoskeletal tissue. Published research does not position one wavelength as superior to the other in an absolute sense. Rather, the literature establishes that each is optimal for a different depth range, and a full-body system that covers only one range leaves vital physiological targets unaddressed during the session.

A 2014 paper by Karu noted that multiple wavelengths act on both mitochondrial and non-mitochondrial photoacceptors, and that tissue heterogeneity across the body means no single wavelength uniformly addresses all targets in a full-body session. Dual-wavelength coverage is therefore a structural feature of a proper protocol, not an optional enhancement. Clients with skin-focused goals draw primarily from 635nm coverage, while clients with musculoskeletal goals draw from 850nm. Most clients benefit from both simultaneously.

The OvationULT emits both 635nm red and 850nm near-infrared in a single session, delivering the dual-wavelength coverage that the published literature identifies as standard for commercial full-body photobiomodulation. The device carries FDA Registration #3010627475 (ILY product code) as a Class II medical device, reflecting strict regulatory oversight of the manufacturing and quality processes. Registered indications for the OvationULT include topical heating, temporary relief of minor muscle and joint pain and stiffness, temporary relief of minor arthritis pain, relaxation of muscle spasms, and temporary increase of local circulation.

Wavelength Comparison: 635nm vs 850nm at a Glance

FAQ: 635nm and 850nm in Commercial Red Light Therapy

What is the difference between 635nm and 850nm light in PBM research?

Published research indicates that 635nm red light penetrates approximately 1 to 2mm into tissue and acts primarily on superficial structures, including skin and epidermal layers. Meanwhile, 850nm near-infrared light penetrates approximately 3 to 5cm, reaching deeper musculoskeletal tissue, joints, and tendons. Both wavelengths target cytochrome c oxidase in the mitochondrial respiratory chain, but their anatomical reach differs significantly.

Why does the wavelength specification matter when choosing a red light therapy system?

Wavelength determines where in the body light energy is absorbed. A system emitting only one wavelength addresses only one depth range. A system emitting both 635nm and 850nm addresses the full depth spectrum from the skin surface to deep tissue in a single session. For operators running a general clientele with varied goals, dual-wavelength coverage means each session delivers energy across the complete physiological target range.

What does "biphasic dose-response" mean in practice for an operator?

The biphasic dose-response curve means that cellular stimulation from PBM increases with dose up to an optimal point, then declines or reverses at higher doses. For operators, this means that longer sessions at high irradiance are not categorically better than properly calibrated shorter sessions. Dose (J/cm²) is the product of both irradiance and time, so they must be specified together. The OvationULT's 65 mW/cm² irradiance paired with 10 to 20 minute sessions is designed to deliver a dose within the published stimulatory range without overshooting into inhibitory territory.

Is the OvationULT FDA registered for photobiomodulation?

The OvationULT is FDA registered (Registration #3010627475), which reflects regulatory oversight of the device as a Class II medical device. The device's registered indications include topical heating, temporary relief of minor muscle and joint pain and stiffness, temporary relief of minor arthritis pain, relaxation of muscle spasms, and temporary increase of local circulation.

How does 65 mW/cm² irradiance affect session length and operator throughput?

At 65 mW/cm², the OvationULT accumulates dose at a rate sufficient to reach the published therapeutic range within a 10 to 20 minute session. This means a standard two-client-per-hour throughput model is entirely achievable. Systems with lower irradiance require extended sessions to reach an equivalent dose, which reduces throughput, increases per-client room time, and creates scheduling constraints that hurt commercial profitability.

Sources

Recovery centers built around athletic performance and longevity already serve clients who want red light therapy (RLT). The modality fits your existing stack without adding operational friction. Sessions run 10 to 20 minutes, the device plugs into a standard 120V outlet, and staff training is minimal. For operators running membership models between $150 and $300 per month, RLT can be included at no extra cost to anchor retention, or offered as a premium add-on. This guide walks through the throughput math, membership integration, ROI timeline, and the questions every recovery center operator should ask before signing a purchase order.

Why Are Recovery Centers Such a Natural Fit for Red Light Therapy?

Recovery centers have built their business model around stacking modalities that help clients return to baseline after hard training. Cold plunge, infrared sauna, compression boots, cryotherapy, IV therapy, and hyperbaric chambers all share the same goal: reduce the cost of physical effort and help clients come back sooner.

Red light therapy fits that logic without friction. The device is passive, requires no practitioner contact, and delivers a repeatable client experience every session. According to data from the Global Wellness Institute, the global wellness economy represents one of the fastest-growing segments in fitness and lifestyle.

Chains such as Restore Hyper Wellness, Perspire, Remedy Place, and Sweat House LA have demonstrated that multi-modality recovery is a scalable membership business, not a boutique experiment. When a client's gym already offers compression and percussion massage, your center needs a concrete reason to hold their membership. RLT delivers that reason without requiring a licensed practitioner, a consumable supply chain, or a massive footprint.

From a compliance standpoint, commercial RLT devices must meet federal photonic safety standards. The OvationULT carries FDA Registration #3010627475 and is classified as a Class II device with an ILY product code. Body Balance System is FDA registered, which is the correct regulatory designation for photonic medical devices of this class. Confirm equivalent credentials from any vendor before buying.

How Does Red Light Therapy Fit Into an Existing Recovery Modality Stack?

Sequencing matters, and RLT has a clear position in most recovery protocols. The most common sequence starts with training, transitions to red light for local circulation and muscle relaxation, and then moves into contrast therapy like a cold plunge or cryotherapy. Research published in PubMed-indexed journals on photobiomodulation (PBM) has examined local circulation, muscle relaxation, and tissue response. Operators should attribute those findings to general research rather than to a specific device.

Within the ILY scope for the OvationULT, the device is indicated for:

• Topical heating

• Temporary relief of minor muscle and joint pain and stiffness

• Temporary relief of minor arthritis pain

• Relaxation of muscle spasms

• Temporary increase of local circulation

Those indications map directly onto what a post-workout athlete wants: a comfortable 10 to 20 minute session that delivers warmth and relaxation before the cold plunge or the drive home.

Infrared sauna is a natural complement rather than a competitor. Some operators offer RLT first because of its shorter session and lower thermal load, followed by the infrared sauna, and finally a cold plunge as the final contrast. Others pair RLT and compression sleeves in adjacent rooms on overlapping time slots to maximize throughput per square foot. Because the OvationULT runs 10 to 20 minute sessions, the timing aligns neatly with most sauna and compression durations. This ensures clients move through the rotation without awkward waits.

What Does the Throughput Math Actually Look Like?

At a standard 15-minute session within the 10 to 20 minute range, one OvationULT supports 2 clients per hour. Over a 10-hour operating day, that is 20 client sessions per unit. A 12-hour operating day yields 24 sessions per unit. That is the baseline capacity number you need before running a meaningful ROI calculation.

The revenue side depends on how you package RLT. Recovery centers typically choose one of three models:

1. Include RLT in all membership tiers to anchor retention.

2. Offer it as a premium tier upgrade at $20 to $40 per month.

3. Price individual sessions at $25 to $45 for non-members and day-pass clients.

At $35 per session and 60 percent utilization on a 12-hour day, a single unit generates roughly $300 per day, or approximately $9,000 per month. With the OvationULT priced at $59,997, that puts the gross revenue payback period well within the 9 to 18 month range. This is before you even account for membership retention lift, which is often the larger driver.

Staff involvement per session is minimal. The client activates the session, the operator sets the protocol, and the device runs without supervision. That means you are not staffing to RLT capacity the way you would for IV therapy or manual massage. The labor efficiency is one reason RLT has a better margin profile than most other modalities at comparable price points. For a center already paying for front-desk staff to manage cold plunge rotations, adding RLT does not require a headcount increase.

What Membership Pricing Models Work Best for Recovery Centers Adding RLT?

Membership pricing in the recovery center vertical has settled around a few predictable structures:

• Unlimited Tiers: Run $200 to $300 per month with full modality access.

• Mid-Tier Memberships: Sit at $150 to $200 per month, covering core modalities like cold plunge, infrared sauna, and compression, but gating premium add-ons like RLT behind an upgrade.

• Entry Tiers: Run $100 to $150 per month and are typically visit-based, functioning more like discounted punch cards.

The most common strategy is to include RLT in the top one or two membership tiers and market it as the primary differentiator. This lifts average revenue per member as existing members upgrade, and it gives prospects a concrete reason to choose the higher tier. According to ISPA industry data, service bundling is one of the highest-leverage retention tools in facility-based wellness. RLT suits bundling perfectly because it carries no meaningful consumable costs after the hardware purchase.

For day-pass and drop-in clients, individual session pricing at $30 to $45 positions RLT above compression in perceived value but below cryotherapy or IV therapy in intensity. That price point works because the session delivers a tangible experience of warmth and deep relaxation that clients love to talk about. A client who completed a cold plunge and a red light session has a specific story to tell, and that specificity drives referrals.

What Are the Space and Power Requirements for a Commercial RLT Unit?

The OvationULT is a full-body panel system designed for commercial use with a footprint that fits in a standard treatment room or wellness bay. The device runs on a standard 120V outlet. This means no electrical infrastructure upgrades, no dedicated circuit negotiations with your landlord, and no construction permitting delays.

For operators in leased spaces, this is a massive deployment advantage. Adding cryotherapy, hyperbaric oxygen, or high-amperage infrared saunas often requires electrical panel upgrades that add thousands in cost and months of delays to a buildout.

Most operators allocate a private room or semi-private bay for RLT to support the relaxation component of the session. Clients using RLT after a cold plunge often want a quiet, warm environment to complete the contrast cycle, and a shared open-floor configuration works against that experience. An 80 by 31 inch footprint fits comfortably in a standard treatment room.

Protocol simplicity is a real operational advantage. Sessions are 10 to 20 minutes, the device settings are operator-configured in advance, and clients follow a simple orientation script. There is no hands-on contact, no injectable, and no recovery observation period. The net result is that one front-desk staff member can manage RLT rotations alongside other check-in duties without dedicated practitioner time.

What Does the ROI Calculation Look Like?

The ROI framework for RLT in a recovery center has three inputs: hardware cost, revenue per unit per month, and membership retention lift. The OvationULT is priced at $59,997 with a 5-year warranty, so operators can amortize the cost over 60 months with near-zero maintenance expense. Amortized over 60 months, the monthly capital cost is approximately $1,000.

Retention value is often the larger number. If RLT in the top tier keeps 10 percent of a 300-member base for just one additional month per year at $250 per month, that is $7,500 in annualized retained revenue. Combined with direct session revenue, payback on a premium commercial unit falls well inside 12 to 18 months at moderate utilization.

Body Balance System installations at world-class luxury resorts and spas reflect the commercial durability expectations appropriate for a device at this price point. Operators should apply the same due diligence to any purchase: confirm the FDA registration number, ask for commercial references, and get warranty terms in writing before signing.

What Should Recovery Center Operators Ask Any RLT Manufacturer Before Buying?

Buyer due diligence on commercial RLT hardware is not complicated, but most operators skip it.

1. Regulatory Credibility: Ask for the FDA registration number and verify it in the public database. An FDA-registered device has a verifiable public record. An unregistered device carries immense liability that transfers to the operator the moment a client has an adverse event.

2. Irradiance Realities: Ask for measured irradiance at actual treatment distance in mW/cm², and check whether that number comes from independent testing. The OvationULT delivers 65 mW/cm² measured right from the surface. Vendors who quote peak irradiance at contact distance rather than at actual treatment distance are inflating their figures to make up for a lack of design efficiency.

3. Warranty and Service: A device down during peak hours is lost revenue. Ask what the warranty covers, the average service response time, and whether parts are stocked domestically. Body Balance System offers a 5-year warranty on parts and labor for the OvationULT, which is one of the longest coverage periods in the commercial segment.

4. Compliance Boundaries: If a vendor claims recovery time reduction, performance enhancement, or inflammation reduction as direct device claims, they are operating outside their registered scope. Clinical language must be attributed to peer-reviewed research, not the specific device.

FAQ

Q: Can red light therapy be included in a recovery center membership without additional liability concerns?

Yes, provided you use an FDA-registered device and stay within indicated uses: topical heating, temporary relief of minor muscle and joint pain/stiffness, temporary relief of minor arthritis pain, relaxation of muscle spasms, and temporary increase of local circulation.

Q: How many sessions per day can one OvationULT unit realistically handle in a recovery center setting?

At a standard 15-minute session within the 10 to 20 minute range, the unit supports 2 clients per hour. A 12-hour operating day yields approximately 24 sessions at full utilization. Most operators plan for 60 to 75 percent utilization as a conservative revenue baseline, which puts realistic daily sessions at 14 to 18 per unit.

Q: Does adding red light therapy require additional staff in a recovery center?

No dedicated practitioner is required. Sessions run 10 to 20 minutes, the protocol is set by the operator in advance, and clients follow a brief orientation. Front-desk staff can manage RLT rotations alongside standard check-in duties without additional headcount.

Q: How does the OvationULT compare to consumer-grade red light panels in a commercial setting?

The OvationULT is built for high-volume commercial duty, whereas consumer panels often lack FDA registration for commercial applications, commercial-grade duty cycles, business warranty coverage, and verified high irradiance (65 mW/cm²) at actual treatment distance.

Q: What is the best placement of RLT in a recovery center session sequence?

Most operators sequence RLT after training or exertion and before a cold plunge or cryotherapy. The warming and local circulation effects of a 10 to 20 minute session serve as an excellent bridge between the exertion phase and cold contrast therapy.

Sources

OSHA requires that electrical equipment used in U.S. workplaces be tested and certified by a Nationally Recognized Testing Laboratory (NRTL), per 29 CFR 1910.303. Red light therapy equipment installed in a commercial setting qualifies as workplace electrical equipment. Yet the certification question rarely appears in vendor conversations or online comparisons. This guide explains what NRTL certification is, which labs are recognized, how it differs from FDA registration, what relevant safety standards apply to light-emitting equipment, how to verify any manufacturer's listing, and what exposure an operator takes on when they skip this due diligence.

NRTL Certification for Red Light Therapy: What It Is, Why It Matters, and How to Verify

The commercial red light therapy market has moved past the early-adopter phase. According to Grand View Research, the global market reached $533.8 million in 2025 and is projected to hit $587.5 million in 2026, with a compound annual growth rate of 9.8% through 2033. The B2B segment, covering medspas, wellness centers, hospitality facilities, and clinical practices, accounted for the largest revenue share in 2025. Six forces are reshaping the market right now: accelerating vertical adoption across new facility types, a more complex FDA regulatory landscape, private equity consolidation in adjacent wellness equipment categories, growing pressure for irradiance and methodology transparency, supply chain sourcing risk from white-label proliferation, and a tightening 12-to-24-month window for operators to establish market position before competition intensifies.

How Big Is the Commercial RLT Market in 2026, and How Fast Is It Growing?

The numbers tell a consistent story, even if different research firms measure the market at different scales. Grand View Research places the global red light therapy market at $533.8 million for 2025, growing to $587.5 million in 2026 at a 9.8% CAGR through 2033. The broader red light therapy beds segment shows steeper growth projections: Coherent Market Insights estimates the global beds market at $9.29 billion in 2026, reaching $19.56 billion by 2033 at a 13.2% CAGR. The bed-focused figure reflects a wider product scope that includes consumer formats, but both data sets point in the same direction.

B2B channels, covering medspas, wellness centers, rehabilitation centers, and hospitality facilities, still account for the largest revenue share in absolute terms. The B2C segment (home-use panels and portable devices) now carries the fastest CAGR in the forecast period, per Grand View Research, which reflects the consumer awareness wave feeding commercial demand downstream. North America holds a 44.6% global market share, while Asia Pacific is the fastest-growing region.

The broader wellness economy provides important context. According to the Global Wellness Institute's 2025 Wellness Economy Monitor, the global wellness economy reached $6.8 trillion in 2024 (up 7.9% from 2023), with a projected expansion to $9.8 trillion by 2029. The GWI specifically names infrared light therapy and photobiomodulation among the longevity and biohacking approaches now ubiquitous in fitness centers, spas, and resorts. RLT is not a niche add-on. It is becoming a standard facility offering.

Commercial RLT Market Size and Growth Projections 2025-2033

What Verticals Are Driving Commercial RLT Adoption?

Medspas are the anchor vertical. Consumer demand for non-surgical, non-injectable service options has grown at mid-to-high single-digit rates, according to data reviewed by the American Med Spa Association. Red light therapy slots in as a standalone service, a membership anchor, or an add-on to aesthetic treatments. The Fortune Business Insights light therapy market report notes that dermatology clinics and medical spas are primary buyers of commercial red light therapy devices, with red light holding approximately 34% of the total light therapy market share.

Hospitality is the fastest-growing commercial segment from a smaller base. Hotels and hospitality facilities are explicitly part of the B2B segment driving growth, per Grand View Research. The Global Wellness Institute notes that governments and hospitality brands are investing in therapeutic modalities to differentiate properties as wellness tourism expands. Properties such as Four Seasons, Fairmont, and Canyon Ranch have deployed commercial-grade red light therapy beds as premium amenity offerings, recognizing that equipment quality reflects on the property's overall wellness positioning.

Chiropractic, rehabilitation, and recovery-focused fitness facilities represent the next adoption wave. The Fortune Business Insights report cites rising demand from orthopedic and chiropractic centers as a specific growth driver. For these operators, the business case is direct: sessions run 10-20 minutes, setup is minimal, and the modality integrates into existing scheduling without adding staff. The Grand View Research data notes Precor partnered with Wellness USA in October 2024 to distribute RLT equipment across fitness facilities, spas, and hotels globally, signaling the mainstream fitness equipment channel treating RLT as a standard offering. Muscle recovery applications are projected to show the fastest CAGR among application segments through 2033.

Vertical Adoption Curve for Commercial Red Light Therapy 2024-2026

How Is the FDA Regulatory Landscape Shifting?

The FDA landscape for commercial red light therapy devices operates on two distinct tracks.

The first is the ILY product code (Infrared Lamp for Heating). Devices listed under ILY are Class II medical devices registered with the FDA. Registration means the manufacturer has submitted facility and device information to the FDA's device database, not that the device has undergone premarket review for specific clinical claims. ILY registration is the appropriate pathway for full-body commercial beds used for topical heating, temporary relief of minor muscle and joint pain and stiffness, temporary relief of minor arthritis pain, relaxation of muscle spasm, and temporary increase of local circulation. Body Balance System holds FDA Registration number 3010627475 under the ILY product code.

The second track is the OLH product code, covering phototherapy devices for skin conditions. OLH devices go through the 510(k) premarket notification pathway and can make specific claims tied to their cleared intended use, such as treatment of facial wrinkles or acne. The FDA's public 510(k) database shows a meaningful uptick in OLH filings, with multiple Shenzhen-based manufacturers receiving clearances in late 2025 and early 2026 (see K253400 and K252603).